# US 2021/0171949 A1 · Targeting Mirnas for Exosomal Delivery or Cellular Retention

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171949 A1
- Document ID: US20210171949A1
- Status: Published application
- Kind: A1
- Application number: 17/156,145
- Filed: 2021-01-22
- Published: 2021-06-10
- Earliest claimed: 2018-07-26
- Assignees: Joslin Diabetes Center, Inc.
- Applicants: Joslin Diabetes Center
- Inventors: C. Ronald Kahn; Ruben Garcia Martin
- Web page: https://patentgrep.com/patent/US20210171949A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/1277: Preparation processes; Proliposomes
- A61K 9/5176: {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/5123)}
- A61K 35/34: Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes (vascular smooth muscle A61K35/44)
- A61K 35/35: Fat tissue; Adipocytes; Stromal cells; Connective tissues (adipose-derived stem cells A61K35/28; collagen A61K38/39)
- A61K 35/407: Liver; Hepatocytes
- A61K 35/44: Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N 2320/50: Methods for regulating/modulating their activity
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed herein are exosomal sorting motifs and cellular retention motifs for microRNAs. Methods of use for directing miRNA to exosomes or retaining miRNA in cells are also disclosed.

## Claims

### Claim 1

A method for producing exosomes or exosome-like vesicles comprising miRNA in vitro comprising:
a. modifying a miRNA to include at least one exosomal sorting motif and/or removing any cellular retention motifs;
b. introducing the modified miRNA into a cell capable of producing an exosome or exosome-like vesicle under conditions that will result in expression of the modified miRNA; and
c. optionally, collecting the produced exosomes or exosome-like vesicles, wherein the exosomal sorting motif is UGUG, GGAG, CAUG, GGCA/G, A/CGGG, CUGG, or CGGGAG and the cell retention motif, if present, is CAGU, ACAG, AUUG, UAGC, or CCCG.

### Claim 2

A method of treating a subject in need of gene silencing comprising administering to the subject an exosome, wherein the exosome is produced in vitro by a) modifying a miRNA to include at least one exosomal sorting motif and/or removing any cellular retention motifs, and b) introducing the modified miRNA into an exosome- or exosome-like vesicle producing cell under conditions that will result in expression of the modified miRNA, and collecting the produced exosome comprising the modified miRNA, wherein the exosomal sorting motifs is selected from UGUG, GGAG, CAUG, GGCA/G, A/CGGG, CUGG, and CGGGAG and the cellular retention motif, if present, is selected from CAGU, ACAG, AUUG, UAGC, and CCCG.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the miRNA comprises one exosomal sorting motif.

### Claim 4 (depends on 1, 2)

The method of claim 1 or 2, wherein the miRNA comprises more than one exosomal sorting motif.

### Claim 5 (depends on 1)

The method of claim 1, further comprising administering the exosome or exosome-like vesicle to a subject.

### Claim 6 (depends on 1, 2)

The method of claim 1 or 2, wherein modifying the miRNA with an exosomal sorting motif results in more miRNA in the exosome as compared to an exosome produced with a miRNA not modified with an exosomal sorting motif.

### Claim 7 (depends on 1, 2)

The method of claim 1 or 2, wherein the removal of the cellular retention motif results in more miRNA in the exosome as compared to an exosome produced with a miRNA comprising a cellular retention motif.

### Claim 8 (depends on 1, 2)

The method of claim 1 or 2, wherein the miRNA contains a cell retention motif and wherein the cell retention motif is removed.

### Claim 9

A method for retaining miRNA inside a cell in vitro comprising:
a. modifying a miRNA to include at least one cell retention motif and/or removing any exosomal sorting motifs; and
b. introducing the modified miRNA into a cell capable of producing an exosome or exosome-like vesicle under conditions that will result in expression of the modified miRNA, wherein the cell retention motif is CAGU, ACAG, AUUG, UAGC, or CCCG, and the exosomal sorting motif, if present is UGUG, GGAG, CAUG, GGCA/G, A/CGGG, CUGG, or CGGGAG.

### Claim 10

A method for treating a subject in need of gene silencing comprising:
a. collecting the subject's cells and manipulating them ex vivo to express a miRNA having at least one cellular retention motif and/or removing any exosomal sorting motifs, and
b. administering the ex vivo manipulated cell comprising the modified miRNA to the same or different subject from which it was collected, wherein the cellular retention motif is selected from CAGU, ACAG, AUUG, UAGC, and CCCG, and the exosomal sorting motif, if present, is selected from UGUG, GGAG, CAUG, GGCA/G, A/CGGG, CUGG, and CGGGAG.

### Claim 11 (depends on 9, 10)

The method of claim 9 or 10, wherein the miRNA comprises one cellular retention motif.

### Claim 12 (depends on 9, 10)

The method of claim 9 or 10, wherein the miRNA comprises more than one cellular retention motif.

### Claim 13 (depends on 9, 10)

The method of claim 9 or 10, wherein the addition of the cellular retention motif reduces the export of the miRNA into an exosome or exosomal-like vesicle.

### Claim 14 (depends on 9, 10)

The method of claim 9 or 10, wherein the removal of the exosomal sorting motif reduces the export of the miRNA into an exosome or exosomal-like vesicle.

### Claim 15 (depends on 9)

The method of claim 9, further comprising administering the cell to a subject.

### Claim 16 (depends on 10, 15)

The method of claim 10 or 15, wherein the miRNA levels in non-implanted cell-types after administration to the subject are reduced as compared to levels in subject administered a non-modified miRNA containing cell.

### Claim 17

The method of any one of the preceding claims, wherein the cell is an adipocyte, muscle cell, hepatocyte, or vascular endothelial cell.

### Claim 18 (depends on 17)

The method of claim 17, wherein the adipocyte is a white adipocyte or brown adipocyte.

### Claim 19 (depends on 18)

The method of claim 18, wherein the white adipocyte is a 3T3-L1 cell.

### Claim 20 (depends on 18)

The method of claim 18, wherein the brown adipocyte is a BAT cell.

### Claim 21 (depends on 17)

The method of claim 17, wherein the muscle cell is a C2C12 cell.

### Claim 22 (depends on 17)

The method of claim 17, wherein the hepatocyte is an AML12 cell.

### Claim 23 (depends on 17)

The method of claim 17, wherein the vascular endothelial cell is a SVEC cell.

### Claim 24 (depends on 1, 2)

The method of claim 1 or 2, wherein the cell is a hepatocyte or endothelial cell and the exosomal sorting motif is A/CGGG; CUGG; GGAG; or CGGGAG.

### Claim 25 (depends on 1, 2)

The method of claim 1 or 2, wherein the cell is a brown or white adipocyte or muscle cell and the exosomal sorting motif is UGUG; CAUG; CUGG; or CGGGAG.

### Claim 26

The method of any one of the preceding claims, wherein the miRNA is any one of the miRNAs of SEQ ID Nos: 1-704.
